Wellbutrin XR vs XL: Formulation and Clinical Differences
Wellbutrin XR and Wellbutrin XL are the same medication—both are once-daily extended-release formulations of bupropion that are bioequivalent and clinically interchangeable. 1, 2, 3
Nomenclature Clarification
The terms "XR" (extended release) and "XL" (extended release) refer to identical formulations marketed under different names in different regions; in the United States, the product is labeled as Wellbutrin XL, while some international markets use the designation Wellbutrin XR. 1, 2
Both deliver the same pharmacokinetic profile: once-daily dosing with a time to peak concentration (Tmax) of approximately 5 hours, compared to approximately 3 hours for the sustained-release (SR) formulation and approximately 1.5 hours for the immediate-release (IR) formulation. 3
Bioequivalence Across All Bupropion Formulations
All three bupropion formulations—IR (three times daily), SR (twice daily), and XL/XR (once daily)—are bioequivalent in terms of total systemic exposure to bupropion and its active metabolites when dosed appropriately. 1, 2, 3
Specifically, Wellbutrin XL 300 mg once daily produces the same area under the curve (AUC) and peak plasma concentration (Cmax) as bupropion IR 100 mg three times daily or bupropion SR 150 mg twice daily. 4, 3
This bioequivalence extends to the three active metabolites—hydroxybupropion (the primary metabolite formed by CYP2B6), threohydrobupropion, and erythrohydrobupropion—all of which contribute to the antidepressant effect. 3, 5
Clinical Efficacy and Therapeutic Equivalence
The antidepressant efficacy of Wellbutrin XL was established by demonstrating bioequivalence to the IR and SR formulations, which had already proven effectiveness in placebo-controlled trials for major depressive disorder. 4, 1
In direct comparative trials, bupropion XL showed similar efficacy to escitalopram (an SSRI) and venlafaxine XR (an SNRI) in treating major depressive disorder, with the advantage of significantly lower rates of sexual dysfunction (approximately 8% vs 18–30% with SSRIs). 6, 1, 2
For seasonal affective disorder, Wellbutrin XL 300 mg once daily (mean doses 257–280 mg/day) achieved depression-free rates of 84.3% versus 72.0% for placebo across three combined trials. 4
Dosing and Administration
Wellbutrin XL/XR should be administered once daily in the morning to align with its extended-release design and minimize insomnia risk. 6
Standard initiation: 150 mg once daily for the first 3 days, then increase to 300 mg once daily if tolerated; the maximum recommended dose is 450 mg per day. 6
The second dose timing issue that applies to SR formulations (must be taken before 3 PM) does not apply to XL/XR, which is dosed only once daily in the morning. 6
When to Choose SR Over XL/XR
Bupropion SR is the appropriate choice when twice-daily dosing is required, such as for patients who cannot swallow large tablets whole (SR tablets are smaller) or those needing flexible dosing (e.g., a total daily dose of 150 mg, which is easier to achieve with SR). 6
The SR formulation provides the same total daily exposure as XL when dosed at 150 mg twice daily (equivalent to XL 300 mg once daily), but requires the second dose to be taken before 3 PM to avoid insomnia. 6
Safety Profile and Contraindications
The seizure risk with Wellbutrin XL is approximately 0.1% (1 in 1,000 patients) at therapeutic doses up to 300 mg/day, which is identical to the SR formulation and lower than the 0.4% risk seen with higher doses of the IR formulation. 4
Absolute contraindications apply equally to all formulations: history of seizure disorder, conditions that lower seizure threshold (eating disorders, stroke, brain metastases), current or recent (within 14 days) MAOI use, and abrupt discontinuation of alcohol or benzodiazepines. 6, 4
Serious hypersensitivity reactions (severe rash, angioedema, respiratory compromise) occur in approximately 1 in 1,000 to 1 in 10,000 patients; one case report documented tolerance of SR after a delayed-onset urticaria and angioedema reaction to XL, suggesting possible inactive-ingredient differences, though this is rare. 6, 7
Practical Considerations
Patients should be informed that Wellbutrin XL, Wellbutrin SR, and Wellbutrin (IR) all contain the same active ingredient (bupropion) and must not be combined with each other or with Zyban (bupropion for smoking cessation). 4
In hepatic impairment (moderate to severe cirrhosis), the maximum dose of any formulation should not exceed 150 mg daily (or every other day in severe cases) due to substantially increased bupropion and metabolite accumulation. 6, 4
In moderate to severe renal impairment, reduce the total daily dose by 50% for any formulation. 6